IBEX 35
10.854,70 -17,30 (-0,16%) Euro Stoxx 50
4.921,48 +30,87 (+0,63%) Dólar/Euro
1,0765 +0,0038 (+0,36%) Petróleo Brent
82,32 -0,71 (-0,86%) Oro
2.310,10 +0,50 (+0,02%) Bitcoin EUR
59.719,09 +586,23 (+0,99%)
PTC Therapeutics, Inc. (PTCT)
Después del cierre:
PTC Therapeutics, Inc.
100 Corporate Court
South Plainfield, NJ 07080
United States
908 222 7000
https://www.ptcbio.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 988
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Matthew B. Klein F.A.C.S., M.D., M.S. | CEO & Director | 1,24M | N/A | 1973 |
| Dr. Stuart W. Peltz Ph.D. | Co-Founder, Senior Consultant & Member of Scientific Advisory Board | 796,9k | N/A | 1960 |
| Dr. Allan Steven Jacobson Ph.D. | Co-Founder, Chairman of Scientific Advisory Board & Independent Director | 145k | N/A | 1946 |
| Mr. Pierre Gravier M.S. | Chief Financial Officer | 619,92k | N/A | 1986 |
| Mr. Mark Elliott Boulding | Executive VP & Chief Legal Officer | 761,94k | 1,27M | 1961 |
| Mr. Eric Pauwels | Chief Business Officer | 761,18k | N/A | 1961 |
| Dr. Lee Golden M.D., Ph.D. | Executive VP & Chief Medical Officer | 716,78k | N/A | 1968 |
| Ms. Christine Utter | Senior VP, Chief Accounting Officer & Head of People Services | 595,54k | 995,57k | 1978 |
| Dr. Neil Almstead Ph.D. | Chief Technical Operations Officer | 829,97k | N/A | 1967 |
| Alex Kane | Investor Relations Officer | N/A | N/A | N/A |
Descripción
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Gobierno corporativo
El ISS Governance QualityScore de PTC Therapeutics, Inc., a día 1 de mayo de 2024, es 5. Las puntuaciones base son Auditoría: 7; Tablero: 2; Derechos de los accionistas: 7; Compensación: 6.
